-

$undefined

N/A

(N/A)

Arcus Biosciences NYSE:RCUS Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Location: 3928 Point Eden Way, Hayward, CA, 94545, United States | Website: https://www.arcusbio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

90.97M

Cash

997M

Avg Qtr Burn

-75.0M

Short % of Float

16.56%

Insider Ownership

5.18%

Institutional Own.

94.48%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Quemliclustat + Gemcitabine/Nab-Paclitaxel v.s. Gemcitabine/Nab-Paclitaxel Details Cancer, 1L Pancreatic ductal adenocarcinoma (PDAC)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Domvanalimab + Zimberelimab + Chemo vs. Pembrolizumab + Chemo Details Cancer, 1L Non-small cell lung carcinoma (PD-L1 all-comers)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Domvanalimab + Durvalumab v.s. Durvalumab Details Cancer, Unresectable Stage 3 Non-small cell lung carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Domvanalimab + Zimberelimab + Chemo v.s. Nivolumab + Chemo Details Cancer, Gastrointestinal stromal tumors, Gastroesophageal junction tumors, Gastroesophageal adenocarcinomas	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Casdatifan + Cabozantinib Details Cancer, Solid tumor/s, Renal cell carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Casdatifan + Cabozantinib v.s. Cabozantinib Details Cancer, Post-IO clear cell renal cell carcinoma (ccRCC)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Domvanalimab +/- Zimberelimab +/- Sacituzumab govitecan-hziy or other combos Details Cancer, 1L/2L Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Domvanalimab +/- Zimberelimab +/- Chemo Details Cancer, Esophageal cancer, Gastroesophageal junction tumors, Gastric cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etrumadenant + Atezolizumab Details Cancer, Pancreatic cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etrumadenant + Zimberelimab + mFOLFOX v.s. Standard of care Details Cancer, Colorectal cancer , Metastatic colorectal cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Domvanalimab +/- Zimberelimab +/- Quemliclustat +/- Chemo Details Cancer, 1L/2L Non-small cell lung carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Casdatifan + Zanzalintinib Details Cancer, Renal cell carcinoma, Solid tumor/s	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AB598 Details Cancer, Advanced malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AB801 Details Cancer, Advanced malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quemliclustat +/- Zimberelimab Details Cancer, 1L Pancreatic ductal adenocarcinoma (PDAC)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Casdatifan + Cabozantinib Details 2L+ clear cell renal cell carcinoma (ccRCC)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etrumadenant + Zimberelimab + Docetaxel Details Cancer, Prostate cancer, Castration-resistant prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.